PDS Biotechnology Corporation filed an amended annual report to add detailed Part III information on its board, executive team, compensation, ownership and auditor fees for the year ended December 31, 2025. The amendment does not change previously reported financial results.
The company reports aggregate market value of common equity held by non-affiliates of $60,145,221 as of June 30, 2025, and 55,815,653 common shares outstanding as of March 23, 2026. It describes a classified board structure, committee memberships, independence determinations, executive pay (including salary, options and severance terms), equity incentive and inducement plans, and KPMG LLP audit fees.
PDS Biotechnology Corporation amended its Form S-3 registration to register an aggregate initial offering price of $200,000,000 of common stock, preferred stock, debt securities, warrants, units and rights. The amendment updates Nasdaq market price information, removes a prior at-market sales agreement covering up to $20.0 million, files updated exhibits including a KPMG LLP consent, and makes related conforming changes to the prospectus.
The prospectus states the last reported Nasdaq sale price was $0.9281 per share and reports a public float of $73,989,796 based on 54,404,262 shares held by non-affiliates (price cited from April 15, 2026). Shares outstanding were 55,815,653 as of April 23, 2026.
PDS Biotechnology filed an 8-K to share an updated April 2026 corporate presentation highlighting its cancer immunotherapy pipeline. The deck focuses on lead HPV16-targeted drug PDS0101, which showed a median overall survival of 39.3 months in recurrent/metastatic head and neck cancer, compared with a 12–18 month benchmark for Keytruda-based regimens. In a prior Phase 2 study, PDS0101 plus pembrolizumab achieved a 77.4% disease control rate and a 35.8% overall response rate, with 21% of patients experiencing 90–100% tumor regression.
The company is running the VERSATILE‑003 pivotal Phase 3 trial in first-line HPV16‑positive recurrent/metastatic head and neck cancer, with FDA alignment on progression-free survival as an interim primary endpoint for an accelerated approval pathway. Beyond PDS0101, the presentation details tumor-targeting IL‑12 antibody-drug conjugate PDS01ADC in multiple Phase 2 trials across colorectal, prostate and liver-associated cancers, and outlines upcoming data readouts through 2027.
PDS Biotechnology Corporation reported positive interim results from Stage 1 of an NCI-led Phase 2 trial of its tumor-targeted IL‑12 immunocytokine PDS01ADC in metastatic colorectal cancer with liver metastases. In nine patients who had failed at least one prior chemotherapy line, adding PDS01ADC to hepatic artery infusion pump therapy produced a 78% objective response rate, compared with 35% in a parallel trial without PDS01ADC. The two-year survival rate exceeded 80%, versus about 35% in the parallel trial, in this largely immunotherapy‑resistant microsatellite stable or mismatch repair‑proficient population.
PDS Biotechnology Corporation files its annual report describing a clinical-stage immunotherapy pipeline focused on cancer and infectious disease. The company is built around its Versamune T cell activator, PDS01ADC IL‑12 antibody–drug conjugate, and Infectimune vaccine platform, with multiple Phase 2 and Phase 3 oncology trials underway, including the VERSATILE-003 head and neck cancer study.
PDS Biotech remains pre-revenue and reported a net loss of $34.5 million for the year ended December 31, 2025, slightly improved from $37.6 million in 2024. As of that date, it had $26.7 million in cash and cash equivalents and an accumulated deficit of $216.6 million, underscoring ongoing funding needs to support its development programs.
As of March 23, 2026, 55,815,653 common shares were outstanding, and the aggregate market value of non‑affiliate equity was $60.1 million as of June 30, 2025. Management highlights extensive intellectual property around its platforms, collaborations with institutions such as the National Cancer Institute and MD Anderson, and an experienced leadership team in oncology drug development.
PDS Biotechnology reported full-year 2025 results and detailed progress in its cancer immunotherapy pipeline. Net loss narrowed to $34.5 million, or $0.74 per share, from $37.6 million, or $1.03, in 2024 as operating expenses declined.
Research and development spending fell to $19.0 million and general and administrative expenses to $12.5 million, bringing total operating expenses down to $31.5 million. Cash and cash equivalents were $26.7 million at year-end, with total stockholders’ equity of $9.3 million and long-term debt of $11.7 million.
The company updated its PDS0101 Phase 3 VERSATILE-003 trial, incorporating progression-free survival as an interim primary endpoint, which it expects will shorten trial duration and reduce costs while keeping overall survival for full approval. PDS Biotech also highlighted new U.S. and Japanese patents that extend Versamune® platform protection into the 2040s.
PDS Biotechnology Corp reported that President and CEO Frank Bedu-Addo received a grant of stock options covering 548,782 shares of the company’s stock. The options were granted at an exercise price of $0.00 per share as an employee stock option award.
According to the terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on his continued service with the company through each vesting date.
PDS Biotechnology Corp reported that Chief Scientific Officer Gregory Conn received an employee stock option grant covering 150,000 shares on January 12, 2026. The option was awarded at an exercise price of $0.00 per share.
According to the vesting terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on Conn’s continued service with the company through each vesting date.
PDS Biotechnology Corp reported that Chief Medical Officer Kirk V. Shepard acquired an employee stock option covering 300,000 shares of common stock. The option was granted as a derivative security and is held directly after the transaction.
According to the vesting terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on Dr. Shepard’s continued service with the company through each vesting date.
Boesgaard Lars reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that Chief Financial Officer Lars Boesgaard received a grant of employee stock options covering 300,000 shares on January 12, 2026. These options give him the right to buy company stock in the future.
The options vest over four years. Twenty‑five percent of the underlying shares will vest and become exercisable on January 12, 2027, and the remaining 75% will vest in 36 equal monthly installments after that date, as long as he continues to serve the company through each vesting date.